- Info
- Significant Ownership
Significant Ownership of ARCH Venture Fund XII, L.P.
- Signature - Title
- ARCH Venture Partners XII, L.P. - its General Partner
- Location
- Chicago, IL
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by ARCH Venture Fund XII, L.P..
Follow Filing Activity
Follow ARCH Venture Fund XII, L.P. and return when a new Schedule 13D/G filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Continue schedule research
Related filing hubs for this reporting manager, useful for reinforcing crawl paths across the schedule cluster.
Significant Ownership of ARCH Venture Fund XII, L.P.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| NMRA | Neumora Therapeutics, Inc. | Common Stock, $0.0001 par value | 19% | $69,289,455 | +$13,162 | 33,965,419 | +0.02% | Kristina Burow | 30 Mar 2026 |
| PRME | Prime Medicine, Inc. | Common Stock, $0.00001 par value | 10% | $80,853,607 | 18,587,036 | Robert Nelsen | 07 Aug 2025 | ||
| MTSR | Metsera, Inc. | Common Stock, $0.00001 par value | 0% | $0 | -$1,403,973,083 | 0 | -100% | ARCH Venture Fund XII, L.P. | 13 Nov 2025 |
Schedules 13D/G Reported by ARCH Venture Fund XII, L.P.:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.